• Users Online: 158
  • Home
  • Print this page
  • Email this page
Home Current issue Ahead of print Search About us Abstracting and Indexing Editorial board Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2014  |  Volume : 9  |  Issue : 4  |  Page : 417-422

Topical cyclosporine a for treatment of dry eye due to chronic mustard gas injury


1 Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran; Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
2 Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
3 Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
4 Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
5 Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad; Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Australia

Correspondence Address:
Yunes Panahi
Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Molla Sadra Street, Tehran 19945
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2008-322X.150803

Rights and Permissions

Purpose: To evaluate the efficacy of topical cyclosporine A (tCsA) for treatment of dry eye disease in patients suffering from chronic ocular complications of mustard gas (MG) injury. Methods: This interventional case series included patients with MG injury suffering from severe dry eye despite receiving artificial tears and punctal plugs. Patients were administered tCsA 0.05% twice daily for 3 months. Severity of the condition was evaluated by measuring tear osmolarity, ocular surface disease index (OSDI), tear break-up time (TBUT), and Schirmer's test at baseline and at the end of study. Results: A total of 34 patients with chronic MG injury and mean age of 47.1 ± 6.5 years were studied. Compared to baseline values, tear osmolarity (301.7 ± 11.5 vs. 286.3 ± 7.9 mOsmol/L, P < 0.001) and OSDI (47.5 ± 7.2 vs. 42.7 ± 7.1, P < 0.001) were significantly improved. Likewise, Schirmer's test (4.6 ± 1.3 vs. 5 ± 1.3 mm, P < 0.001) and TBUT (1.9 ± 1.4 vs. 2.7 ± 1.5 s, P < 0.001) also significantly recovered at the end of the study. Conclusion: TCsA 0.05% reduces tear osmolarity and improves dry eye symptoms and can serve as an efficacious treatment for ocular complications in patients with chronic MG injury.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2185    
    Printed65    
    Emailed0    
    PDF Downloaded322    
    Comments [Add]    
    Cited by others 4    

Recommend this journal